EIF and K.U.Leuven announce milestone partnership

11-Oct-2006

The Katholieke Universiteit Leuven (K.U.Leuven) and the European Investment Fund (EIF) have entered a partnership agreement to create a Centre for drug design and Discovery ("CD3"). CD3 will build upon research carried out in the biomedical field at the K.U.Leuven in order to discover novel therapeutic compounds directed against biological targets which are investigated within the research groups. In this way, the parties intend to further bridge the gap between academic biomedical research and the needs of the applied industrial research. This initiative will boost translational research and technology transfer in the Life Sciences field.

CD3 will source projects from the various research groups in life sciences of the K.U.Leuven, and in second instance from external partners such as other research institutions. It will seek to collaborate with and/or license results to the pharmaceutical and biotech industry.

Other news from the department science

More news from our other portals

So close that even
molecules turn red...